US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
Quick Look
US-listed ArriVent BioPharma's shares fell nearly 47% after its lung cancer drug firmonertinib, licensed from China's Shanghai Allist Pharmaceuticals, failed to meet its primary endpoint in a phase 3 trial, underscoring challenges for Chinese biotech firms expanding overseas.
AI-generated summary
Why It Matters
ArriVent BioPharma acquired exclusive rights to develop and commercialize firmonertinib outside China in 2021, becoming one of the earliest US biotech firms to license a Chinese drug asset. The drug targets NSCLC with EGFR exon 20 insertion mutations.
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial.
Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small cell lung cancer (NSCLC), targeting epidermal growth factor receptor gene mutations including exon 20 insertion.
ArriVent acquired the exclusive rights in 2021 to develop and commercialise the drug outside China, becoming one of the earliest US biotechnology firms licensing Chinese drug assets.
What to Watch
AI outlook — possibilities, not facts
ArriVent BioPharma will likely announce a strategic review of firmonertinib's development within the next few weeks.
Likely · Within weeks
Open Questions
- What specific efficacy or safety data led to the trial's failure?
- Will ArriVent pursue further development of firmonertinib or abandon the program?
- How will this outcome affect future licensing deals between US and Chinese biotech firms?
